Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease - TRAMPOLINE

Erasmus University Medical Centre Rotterdam0 个研究点目标入组 54 人开始时间: 2021年8月3日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Inclusion Criteria:
•Adults with ADPKD diagnosis based on Ravine criteria and/or with PKD1 or PKD2 mutation
•CKD-EPI eGFR = 60 ml/min/1.73m2
•Ability to provide informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 44
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•- Uncontrolled hypertension, defined as an office blood pressure of =160/ =90 mmHg with or without antihypertensive treatment
•- Concomitant use of =3 antihypertensive medications
•- Serum potassium levels >5.5 mmol/L (measured within last 6 months)
•- History of liver disease (excluding liver cysts due to ADPKD)
•- History of heart failure (cardiac ejection fraction < 35%) or cardiac arrhythmia
•- History of diabetes mellitus
•- Active infection or antibiotic therapy
•- Immunosuppressive therapy within the last year
•- Concomitant use of drugs that could influence blood pressure and/or disease progression (Tolvaptan/non-steroidal anti-inflammatory drugs (NSAIDs)/chemotherapy), excluding <3 antihypertensive drugs
•- Actual pregnancy or unwillingness to adhere to reproductive precautions during the duration of the study

发起方

Erasmus University Medical Centre Rotterdam